abatacept

Ligand id: 6891

Name: abatacept

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: abatacept

No information available.
Summary of Clinical Use
Used to treat moderate to severe rheumatoid arthritis and juvenile rheumatoid arthritis. In July 2017, FDA approval was extended to include treatment of active psoriatic arthritis.
A Phase II clinical trial (NCT00505375) has been completed, evaluating the ability of abatacept to stop autoimmune destruction of any remaining active β cells in patients recently diagnosed with type 1 diabetes mellitus- see [4] for an explanation of the rationale behind this therapeutic approach, and [1] which points to some of its drawbacks.
Mechanism Of Action and Pharmacodynamic Effects
Binding of abatacept to CD80/86 (B7 proteins on antigen presenting cells) provides a negative feedback mechanism which results in T-cell deactivation. This action reduces active inflammation.
External links